Senior Research Fellow Pfizer Cambridge, Massachusetts
Medicinal chemistry/ADME design tactics to identify orally-active peptidomimetic-based inhibitors of SARS-CoV2 Main Protease using light speed approaches (Program initiation - March 2020; 1st synthesis of Nirmatrelvir (Sept 2020); FIH Clinical PK study (March 2020).
Learning Objectives:
Understand the light speed elements of the SARS-CoV2 Main Protease discovery program, which led to the identification of the clinical candidate (Nirmatrelvir) in less than 6 months & initiation of FIH clinical study within a year of initiation of the discovey program.
Application of the drug design & preclinical elements to novel first-in-class drug discovery programs.
Data-driven risk taking in candidate identification/nomination during the preclinical discovery phase.
